Great Bay Bio 大湾生物

The innovative biotech startup, Great Bay Bio (GBB), headquartered in Hong Kong, focuses on simplifying and enhancing global bioprocessing through the utilization of AI and cutting-edge technologies. Led by a team of experienced professionals in biopharmaceuticals and AI, GBB aims to address the challenges in drug development, synthetic biology, IVD, and CGT industries. The company has successfully completed three financing rounds, raising over US $30 million, with the most recent being a $15.00M Series A investment on 13 September 2022 led by Gobi Partners, Vectr Ventures, Alibaba Entrepreneurs Fund, AEF Greater Bay Area Fund, Alon Capital Ltd, and Tiger Jade Capital. GBB has developed proprietary AI biotech platforms, including AlfaCell® and AlfaMedX®, and has secured 26 patents, with 12 related to AI and 14 related to biology, to protect these innovations. The company has also formed partnerships with over 20 leading domestic and international companies.